Showing 16,361 - 16,380 results of 27,276 for search '(( 50 ((mean decrease) OR (a decrease)) ) OR ( 50 ((ng decrease) OR (we decrease)) ))', query time: 1.02s Refine Results
  1. 16361

    Dataset_Jianping Sun_Ambient climate exceeds the effects of warming and precipitation treatment on leaf senescence phenology of community in an alpine meadow by Jianping Sun (21569150)

    Published 2025
    “…In this study, we conducted a 7-year (2015-2021) field manipulative experiment (including warming (+2 ºC) using infrared heater, decreased precipitation (-50%), increased precipitation (+100% in 2015 and +50% in 2016-2021) and their interactions) on the Qinghai-Xizang Plateau to investigate how warming, precipitation alterations, and ambient climate jointly influence LSP in an alpine meadow.…”
  2. 16362
  3. 16363
  4. 16364

    Sequences of Primers used for qRT‒PCR. by Shayeste Sadat Baghermanesh (17026911)

    Published 2024
    “…By performing MTT assay we determined the cytotoxic effects of ribociclib on breast cancer cells, as well as determining the IC50 of it. …”
  5. 16365

    Modulation of the Nrf2 signalling pathway in Hct116 colon carcinoma cells by baicalein and its methylated derivative negletein by Susannah Havermann (588768)

    Published 2016
    “…Oroxylin A and negletein showed a comparable redox-active potential, but only negletein (50 μM, 4 h) was able to activate Nrf2.…”
  6. 16366

    <i>Bax</i> Deficiency Prevents Glaucomatous RGC Death by Richard T Libby (33317)

    Published 2013
    “…<div><p>To determine the effects of BAX deficiency on RGC death in glaucoma, we analyzed RGC layer cells at stages with and without glaucomatous optic nerve damage (see <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.0010004#s4" target="_blank">Materials and Methods</a>). …”
  7. 16367
  8. 16368
  9. 16369
  10. 16370
  11. 16371
  12. 16372
  13. 16373
  14. 16374

    Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
  15. 16375

    DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
  16. 16376

    Table_1_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
  17. 16377

    Table_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
  18. 16378

    DataSheet_2_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
  19. 16379

    Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”
  20. 16380

    Table_3_Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Canc... by Miguel J. Gil-Gil (3074085)

    Published 2021
    “…Most of tumors (88%) were triple negative. No significant decreases in LVEF were observed. The mean baseline LVEF was 66.6% (52-86) and after a median follow-up of 5 years, mean LVEF was 66 (54.5-73). …”